TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

NCT00449644 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis

Interventions

DRUG: TMC207
DRUG: Placebo
DRUG: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)

Sponsor

Janssen Infectious Diseases BVBA